CIRM provides funding across five key areas: Infrastructure, Education, Discovery Research, Translational Research, and Clinical Research. By supporting projects at every stage of development, from initial discovery to clinical trials, CIRM drives progress in regenerative medicine and accelerates innovative therapies to patients.
Check out our portfolio of awards below. Click here to see a list of People We’ve Funded. Click here to see a list of our Funded Institutions.
All CIRM Grants
Search Filters »
Institution |
Researcher name |
Grant Type |
Grant Title |
Award Value |
University of California, San Diego |
Thomas J Kipps |
Disease Team Therapy Development III |
Therapeutic Eradication of Cancer Stem Cells with UC-961 (Cirmtuzumab) |
$4,179,598 |
Sangamo BioSciences, Inc. |
Dr. Fyodor D Urnov |
Strategic Partnership II |
A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells |
$2,760,540 |
Human BioMolecular Research Institute |
Dr. John R Cashman |
Patent Assistance Fund Awards |
Intellectual Property for Stem Cell-Related Inventions – HBRI |
$50,000 |
University of California, San Francisco |
Karin Immergluck PhD |
Patent Assistance Fund Awards |
Patent Assistance Fund Proposal – UCSF |
$87,257 |
University of California, Davis |
David McGee |
Patent Assistance Fund Awards |
CIRM Patent Prosecution Assistance Fund for Stem Cell Technologies – UCD |
$48,595 |
University of California, Santa Barbara |
Bernadette McCafferty |
Patent Assistance Fund Awards |
Intellectual Property in Regenerative Bioengineering from CIRM funded research in regenerative medicine at the University of California, Santa Barbara. |
$23,564 |
University of California, Irvine |
Ronnie Hanecak |
Patent Assistance Fund Awards |
CIRM Patent Assistance Fund Application – UCI |
$46,155 |
University of California, Los Angeles |
Adele Rennie |
Patent Assistance Fund Awards |
Patent Assistance Fund – UCLA |
$84,973 |
Stanford University |
Katharine Ku |
Patent Assistance Fund Awards |
Funding for Patent Applications for CIRM-funded Inventions out of Stanford University |
$3,525 |
University of California, San Diego |
Dr. Rubén D. Flores |
Patent Assistance Fund Awards |
Patent Assistance Fund Application – UCSD |
$38,162 |
University of California, San Diego |
Dr. Lawrence S. B. Goldstein |
Early Translational from Disease Team Conversion |
Stem Cell-Derived Astrocyte Precursor Transplants in Amyotrophic Lateral Sclerosis |
$4,139,754 |
University of California, Los Angeles |
Dr. Irvin SY Chen |
Early Translational from Disease Team Conversion |
Development of a humanized mouse model for testing anti-HIV HSPC gene therapy strategies in HIV-1 infected mice. |
$1,505,000 |
University of California, Los Angeles |
Dr. Stanley Nelson |
Early Translational from Disease Team Conversion |
Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy |
$1,823,545 |
University of California, Los Angeles |
Dr. Robert Reiter MD |
Early Translational IV |
Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells |
$4,075,668 |
Human BioMolecular Research Institute |
Dr. John R Cashman |
Early Translational IV |
Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model |
$6,361,369 |
Numerate, Inc. |
Dr. John H Griffin |
Early Translational IV |
Use of human iPSC-derived neurons from Huntington’s Disease patients to develop novel, disease-modifying small molecule structural corrector drug candidates targeting the unique, neurotoxic conformation of mutant huntingtin |
$520,015 |
University of California, Los Angeles |
Dr. Jerome A. Zack Ph.D. |
Early Translational IV |
Stem Cell Programming With Chimeric Antigen Receptors to Eradicate HIV Infection |
$4,925,166 |
University of California, Los Angeles |
Dr. Gerald Lipshutz |
Early Translational IV |
Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders |
$1,801,629 |
University of California, Los Angeles |
Dr. Donald B. Kohn PhD |
Early Translational IV |
Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells |
$1,651,884 |
Salk Institute for Biological Studies |
Dr. Inder M. Verma |
Early Translational IV |
Development of a cell and gene based therapy for hemophilia |
$2,298,634 |
The Scintillon Institute |
Dr. Stuart A Lipton |
Early Translational IV |
Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke |
$1,103,185 |
Sanford Burnham Prebys Medical Discovery Institute |
Dr. Stuart A Lipton |
Early Translational IV |
Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke |
$1,020,815 |
University of California, San Diego |
Professor Alysson R Muotri |
Early Translational IV |
A drug-screening platform for autism spectrum disorders using human astrocytes |
$1,656,456 |
Cedars-Sinai Medical Center |
Dr. Dan Gazit |
Early Translational IV |
Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing |
$5,121,514 |
Stanford University |
Dr. Michele Calos |
Early Translational IV |
Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B |
$1,876,253 |
Gladstone Institutes, J. David |
Dr. Steve M. Finkbeiner |
Early Translational IV |
Development of Novel Autophagy Inducers to Block the Progression of and Treat Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases |
$2,049,053 |
University of California, Irvine |
Dr. Magdalene J Seiler |
Early Translational IV |
Restoring vision by sheet transplants of retinal progenitors and retinal pigment epithelium (RPE) derived from human embryonic stem cells (hESCs) |
$3,998,948 |
ViaCyte, Inc. |
Howard Foyt |
Strategic Partnership I |
Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes |
$9,475,070 |
Bluebird Bio |
David M. Davidson |
Strategic Partnership I |
A Phase 1/2, Open Label Study Evaluating the Safety and Efficacy of Gene Therapy in Subjects with β-Thalassemia by Transplantation of Autologous Hematopoietic Stem Cells Transduced with the Lentiviral Vector LentiGlobin® Encoding the Human β-A-T87Q-… |
$0 |
FUJIFILM Cellular Dynamics |
Deborah Requesens |
hPSC Repository |
The CIRM Human Pluripotent Stem Cell Biorepository – A Resource for Safe Storage and Distribution of High Quality iPSCs |
$9,942,175 |
Cellular Dynamics International |
Dr. Thomas J Novak |
hiPSC Derivation |
Generation and characterization of high-quality, footprint-free human induced pluripotent stem cell lines from 3,000 donors to investigate multigenic diseases |
$16,000,000 |
University of California, San Diego |
Dr. Joseph G. Gleeson |
Tissue Collection for Disease Modeling |
CIRM Tissue Collection for Neurodevelopmental Disabilities |
$830,426 |
University of California, San Diego |
Dr. Kang Zhang M.D. |
Tissue Collection for Disease Modeling |
Generation of fibroblast cell lines in patients with common blinding eye diseases |
$1,034,425 |
Stanford University |
Dr. Joseph C. Wu |
Tissue Collection for Disease Modeling |
Tissue Collection for Accelerating iPSC Research in Cardiovascular Diseases |
$1,291,832 |
University of California, San Diego |
Dr. James Brewer |
Tissue Collection for Disease Modeling |
Collection of skin biopsies to prepare fibroblasts from patients with Alzheimer’s disease and cognitively healthy elderly controls |
$643,693 |
Stanford University |
Dr. Joachim Franz Hallmayer |
Tissue Collection for Disease Modeling |
Induced pluripotent stem cells from children with autism spectrum disorders |
$530,265 |
University of California, Los Angeles |
Dr. Brigitte N Gomperts |
Tissue Collection for Disease Modeling |
Using human induced pluripotent stem cells to improve our understanding of Idiopathic Pulmonary Fibrosis |
$811,231 |
University of California, San Francisco |
Jacquelyn J Maher |
Tissue Collection for Disease Modeling |
iPSC-derived Hepatocytes as Platforms for Research in Viral Hepatitis and Non-alcoholic Steatohepatitis |
$791,680 |
Reza Ardehali |
Dr. Reza Ardehali MD, PhD |
New Faculty Physician Scientist |
Medical School Loan Repayment Program |
$35,511 |
Tippi C. Mackenzie |
Dr. Tippi C. Mackenzie MD |
New Faculty Physician Scientist |
Medical School Loan Repayment Program |
$36,436 |
Ali Nsair |
Ali Nsair |
New Faculty Physician Scientist |
Medical School Loan Repayment Program |
$120,312 |
University of California, San Francisco |
Dr. Tippi C. MacKenzie |
New Faculty Physician Scientist |
In Utero Embryonic Stem Cell Transplantation to Treat Congenital Anomalies |
$2,661,742 |
Cedars-Sinai Medical Center |
Dr. Robert H Baloh |
New Faculty Physician Scientist |
Human iPSC modeling and therapeutics for degenerative peripheral nerve disease |
$3,031,737 |
Stanford University |
Alan G Cheng |
New Faculty Physician Scientist |
Enhancing hair cell regeneration in mouse and human inner ear |
$3,088,525 |
University of California, San Francisco |
Dr. Ophir Klein MD, PhD |
New Faculty Physician Scientist |
Stem cell therapy for inflammatory bowel disease |
$3,019,013 |
Stanford University |
Michelle Monje |
New Faculty Physician Scientist |
White matter neuroregeneration after chemotherapy: stem cell therapy for “chemobrain” |
$2,800,526 |
University of California, San Francisco |
Jason Harris Pomerantz |
New Faculty Physician Scientist |
Characterization of Human Skeletal Muscle Stem Cells for Clinical Application |
$2,959,014 |
University of California, San Francisco |
Ann Capela Zovein |
New Faculty Physician Scientist |
Human endothelial reprogramming for hematopoietic stem cell therapy. |
$2,197,683 |
University of California, Davis |
Emanual Michael Maverakis |
New Faculty Physician Scientist |
Tunable hydrogels for therapeutic delivery of multipotent stem cells. |
$2,771,903 |
University of California, Los Angeles |
Dr. Ali Nsair MD |
New Faculty Physician Scientist |
Human Induced Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cells for Cardiac Cell Therapy. |
$2,316,894 |